These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29339080)

  • 1. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
    Chalfin HJ; Glavaris SA; Malihi PD; Sperger JM; Gorin MA; Lu C; Goodwin CR; Chen Y; Caruso EA; Dumpit R; Kuhn P; Lang JM; Nelson PS; Luo J; Pienta KJ
    J Urol; 2018 Jun; 199(6):1494-1501. PubMed ID: 29339080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
    Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
    Morgan TM; Lange PH; Porter MP; Lin DW; Ellis WJ; Gallaher IS; Vessella RL
    Clin Cancer Res; 2009 Jan; 15(2):677-83. PubMed ID: 19147774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow.
    Ellis WJ; Pfitzenmaier J; Colli J; Arfman E; Lange PH; Vessella RL
    Urology; 2003 Feb; 61(2):277-81. PubMed ID: 12597930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival.
    Wood DP; Banerjee M
    J Clin Oncol; 1997 Dec; 15(12):3451-7. PubMed ID: 9396397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
    Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C
    Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
    Cackowski FC; Wang Y; Decker JT; Sifuentes C; Weindorf S; Jung Y; Wang Y; Decker AM; Yumoto K; Szerlip N; Buttitta L; Pienta KJ; Morgan TM; Taichman RS
    Prostate; 2019 Oct; 79(14):1715-1727. PubMed ID: 31449673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
    Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
    Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
    Friedlander TW; Welty C; Anantharaman A; Schonhoft JD; Jendrisak A; Lee J; Li P; Hough J; Stromlund A; Edwards M; Sangar S; Kobayashi Y; Simko J; Farrokhian N; Lindquist K; Greene S; Ontiveros P; Graf R; Rodriquez A; Suraneni M; Wang Y; Landers M; Carroll P; Cooperberg MR; Dittamore R; Paris PL
    J Urol; 2019 Oct; 202(4):732-741. PubMed ID: 31216253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression.
    Palermo G; Bassi P; Racioppi M; Recupero SM; Sacco E; Campetella M; Canu G; Pinto F
    Minerva Urol Nefrol; 2020 Apr; 72(2):214-222. PubMed ID: 31144490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKX3.1 as a marker of prostatic origin in metastatic tumors.
    Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
    Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells.
    Polascik TJ; Wang ZP; Shue M; Di S; Gurganus RT; Hortopan SC; Ts'o PO; Partin AW
    J Urol; 1999 Sep; 162(3 Pt 1):749-52. PubMed ID: 10458358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.